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New psychoactive substances (NPS) are an increasing problem around the world [1] . 30 Benzodiazepines are one of a number of groups of NPS that have appeared on the illicit drug 31 market [2] . They also exist as common prescription drugs for anxiety, insomnia and other 32 medical conditions [3] . Benzodiazepines were misused long before emerging as new 33 psychoactive substances and a recent report highlighted the increasing illicit availability and 34 misuse of a clinically-used benzodiazepine, alprazolam, often purchased from the dark web 35 [4] . The new psychoactive substance benzodiazepines (referred to in this work as NPS-36 benzodiazepines) have already been reported in a number of overdose cases, driving under the 37 influence of drugs (DUID) cases and hospital admissions [5] [6] [7] [8] . The lack of control and safety 38 over these NPS-benzodiazepines is a prevalent issue and it is predicted that it will become an 39 even more worrying trend as their misuse continues to rise. A number of these compounds 40 were originally prescription drugs such as phenazepam (Russia) as well as etizolam and 41 flutazolam (Japan) [9] [10] [11] . Some of these compounds never gained marketing approval (e.g. Equation 1 . 
Sodium phosphate buffer (0.01 M) was formulated using deionised water (Barnstead of the solute between these two extremes is a function of the dissociation equilibrium. The 135 effective electrophoretic mobility of a compound can be calculated by using the difference in 136 migration time between the test compound and a neutral marker [35] . 
In Equation , ta is the migration time for the test compound (s), tm is the migration time for the 138 neutral marker (s), Ld is the total length from the capillary inlet to the detection window (cm),
139
Lt is the total capillary length (cm) and V is the applied voltage (V). As a result of the differences 140 in pH there can be variations in electroosmotic flow but these are corrected for by using a 141 neutral compound as a marker and adjusting for this in the calculation of effective mobility. 
Equations (3) and (4) describe the relationship between the effective electrophoretic mobility of a compound and its pKa for benzodiazepines with one ionisable basic group and an ionisable 144 basic and acidic group [36] .
145
Phosphate, acetate and borate buffers were utilised as described elsewhere with a pH spacing 146 of 0.5 pH units [36] . All buffers had an ionic strength of I=0.05 and a concentration of 0.05 M.
147
Sodium chloride was used to adjust the ionic strength and hydrochloric acid (0. Plasma protein binding (PPB) was calculated using the experimental plasma concentration
201
(Pexp) and the experimental buffer concentration (Bexp) according to Equation (5) .
202
(%) = 100 × −
For those benzodiazepines that were highly protein bound and had a concentration in the buffer 203 phase that was below the limit of quantitation (LOQ), the buffer concentration was calculated 204 indirectly using Equation (6) Table 1) .
248
The majority of the NPS-benzodiazepines were fairly lipophilic with log D7.4 values above 2
249
( Table 1) the low lipophilicity for pyrazolam becomes more apparent when its structure is considered.
254
Pyrazolam contains a pyridin-2-yl ring at position 7 rather than a phenyl ring, as is the case 255 with the rest of the benzodiazepines in this study. The phenyl ring has a log D7.4 value of 1.56 256 versus a log D7.4 value of 0.62 for the pyridin-2-yl ring [44] . Replacement of a phenyl ring for 257 a pyridin-2-yl ring could lead to a decrease in lipophilicity. The benzodiazepine bromazepam 258 contains a pyridin-2-yl ring rather than a phenyl ring and has a log D7.4 value of 1.60 [45] . The addition of a triazole ring to some compounds is also known to lead to a decrease in the partition [53, 54] .
280
The presence of an electron-withdrawing hydroxyl group decreases the pKa2 value, as does the 281 presence of an ortho-chlorine substituent on the phenyl ring [55] . (Table 3) .
297
Values for plasma protein binding are listed in Table 3 for clinically used benzodiazepines; 298 wide variations were reported in the literature for many of the benzodiazepines. Age and sex
299
have both been observed as causing differences in the plasma protein binding of drugs which 300 may have been a factor in these variations as many of them were determined in vivo [56] [57] [58] .
301
The experimentally derived values for the reference benzodiazepines were typically within the literature ranges with low variations. reported 60 % plasma protein binding [31] . Substitution of the phenyl ring at position-5 for a 312 pyridin-2-yl ring has been previously reported to lead to a large decrease in lipophilicity for 1,-313 4-benzodiazepines [59] . The same effect could well occur for triazolobenzodiazepines. occurs at the 4' position then no such decrease is observed [59] . This is thought to be as a result of the substitution at the 2'-position affecting the rotation and orientation of the benzene ring 327 and resulting in lower binding. 
379
The software appeared to be less effective at predicting plasma protein binding of the test 380 benzodiazepines than the NPS-benzodiazepines (Table 3) . However an important caveat is that experimental data for these novel psychoactive substances remains preferable to that generated 404 from predictive software. The inclusion of experimental data for these NPS-benzodiazepines 405 could aid the predictive capability of various software packages. 
Supplementary information Benzodiazepine structures
The structures of the NPS-benzodiazepines used in this work are visualised in Figures S1A -C and Tables S1 -3 .
A) 1,4-benzodiazepine B) Triazolobenzodiazepine C) Thienotriazolodiazepine
Figures S1A -C. Basic structure of a 1,4-benzodiazepine, a triazolobenzodiazepine and a thienotriazolodiazepine 
HPLC Method validation
The method was validated in terms of linearity, limit of quantitation (LOQ), limit of detection (LOD), accuracy and precision. This was performed according to the ICH guidelines.
Linearity
The linearity of this method was measured by constructing a five-point calibration plot of the area under the curve (AUC) of each compound against its concentration in mg ml -1 (n=3). The method was linear over the concentration range 0.0004 -0.25 mg ml -1 for all compounds. The residual sum of squares for each compound was reasonably low indicating linear concentration-response and a suitable method (Table S4) .
Limit of detection (LOD) and limit of quantitation (LOQ)
The limits of detection and quantitation were determined from the signal-to-noise ratio. The baseline response of blank samples was recorded. A ratio of 10:1 for the compound response to the baseline response was used for the LOQ and a ratio of 3:1 for the LOD. All compounds generally had good limits of detection and quantitation (Table   S4 ). Pyrazolam exhibited the lowest response to the HPLC method, with a LOQ of 263.9 ng ml -1 and a LOD of 82.0 ng ml -1 .
Accuracy
Accuracy was determined through comparison of the percentage recovery at three concentrations (0.25, 0.01 and 0.0004 mg ml -1 ). Percentage recovery was generally within 2 % and thus deemed to be acceptable (Table 5) .
Precision
Precision was determined from the calculation of the standard deviation and relative standard deviation (RSD) of the compound peak areas at three concentrations (0.25, 0.01 and 0.0004 mg ml -1 ). High levels of precision for all benzodiazepines were recorded (Table S5) . 
